Search Results

1 - 10 of 133 items :

  • pharmacokinetics x
  • Clinical Medicine, other x
Clear All
The Statistical Analysis of Pharmacokinetic Parameters in the Context of Bioequivalence Testing of Two Anthelmintic Formulas Based on Ivermectine and Triclabendazole in Sheep

References 1. Barrera B, Otero JA, Egido E et al. The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. Antimicrob Agents Chemother 2012; 56(7): 3535-3543. 2. Halferty L, Brennan GP, Trudgett A, Hoey L, Fairweather I. Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet Parasitol 2009; 159:126–138. 3. González Canga A, Sahagún Prieto AM, José Diez Liébana M, Martínez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal

Open access
Pharmacokinetics Of Zinc In Broiler Chickens After Single Intraingluvial Administration With Zinc Aspartate

.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for PC. Stuttgart, Jena, New York: Gustav Fisher; 1993. 18. Baggot DJ. The Physiological Basis of Veterinary Clinical Pharmacology. Oxford (UK): Blackwell Science Ltd; 2001. 19. Gibaldi M, Perrier D. Pharmacokinetics, Revised and Expanded. 2nd ed. Swarbrick J, editor. New York: Informa Healthcare Inc; 2007. 20. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:166-75. 21. Ivanova

Open access
The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects

References 1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-99. 2. B Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9. 3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-90. 4. Findling RL. Evolution

Open access
Effect of Food on the Pharmacokinetics of Gliclazide 60 mg Modified Release Tablet in Healthy Caucasian Volunteers

, Lewis BC, et al. Identification of the human cytochromes P450 catalyzing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol. 2007;64(4):450-7. 15. Todor I, Muntean D, Neag M, et al. The influence of CYP2D6 phenotype on the pharmacokinetic profile of atomoxetine in Caucasian healthy subjects. Acta Medica Marisiensis. 2017;63(2):73-9. 16. Rojanasthien N, Autsavakitipong T, Kumsorn B, et al. Bioequivalence study of modified-release Gliclazide tablets in healthy volunteers. ISRN Pharmacol. 2012;2012. doi:10.5402/2012/375134. 17

Open access
The Monitoring of Immunosuppressive Therapy with Tacrolimus in Patients with Kidney Transplant, Based on the Pharmacokinetic Criteria

transplantation. Prilozi 2011;32:87-103. 12. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481–508. 13. Michael F. Crutchlow, Roy D. Bloom. Transplant-associated hyperglycemia: A new look at an old problem.Clin J Am Soc Nephrol 2007;2:343–355. 14. Pirsch J, Bekersky I, Vincenti F et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000;40:527-532. 15. Hasselink DA, Ngyuen H, Wabbijin M et al

Open access
Bioequivalence of indinavir capsules in healthy volunteers

. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998; 42:332-8. 5. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998; 42:2784-91. 6. The United States Pharmacopoeial Convention, Inc. The United States Pharmacopeia 26 / National Formulary 21. Rockville, USA; 2003. 7. Drug Control Division. Thailand Guidelines for the Conduct of

Open access
Comparison of oral bioavailability of acetaminophen tablets, capsules and effervescent dosage forms in healthy volunteers

.: Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharm. 1977;11:283. 9. Srinath K, et al.: Formulation and evaluation of effervescent tablets of paracetamol. INT J Pharm Res Dev. 2011;3:76. 10. Blagden N, et al.: Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007 Jul 30;59(7):617-30 Epub 2007 May 29. 11. De Silva L, et al.: Usability of mobile technology to screen for drugdrug interactions in kidney transplant patients. Am J Nephrol

Open access
Bioequivalence study of cefepime intramuscular injection

References 1. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother. 2004; 53:290-6. 2. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994; 47:471-505. 3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007; 7

Open access
Simultaneous Determination of Carbamazepine and Carbamazepine-10,11-epoxide in Different Biological Matrices by LC-MS/MS

carbamazepine in serum and saliva samples by high performance liquid chromatography with ultraviolet detection Odre đ ivanje karbamazepina u uzorcima seruma i salive primenom te č ne hromatografije visokih performansi sa ultravioletnom de. Vojn Pregl . 2009;66:347-352. 18. Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta . 2014;436:224-236. 19. Beig A, Dahan A. Quantification of carbamazepine and its 10,11-epoxide metabolite in rat plasma by UPLC-UV and application to pharmacokinetic study. Biomed Chromatogr . 2014

Open access
Vitamin D Deficiency and its Importance - A Global Problem of Today, Realistic or Not?

;72(1):213-5. 60. Milovanovic O, Milovanovic JR, Djukic A, et al. Population pharmacokinetics of 25-hydroxyvitamin D in healthy young adults. Int J Clin Pharmacol Ther 2015;53(1):1-8. 61. Gerova DI, Galunska BT, Ivanova II, et al. Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic hepatitis C viral infection. Scand J Clin Lab Invest 2014;74(8):665-72. 62. Borissova AM, Shinkov A, Vlahov J, et al. Vitamin D status in Bulgaria--winter data. Arch Osteoporos 2013;8:133. 63. Laktasić-Zerjavić N

Open access